The findings explain how the brain implements visual working memory and why performance is both limited and variable.

The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.

The new technology delivers results in as little as 30 hours and reduces hands-on time by up to 40 percent, according to the company's data.

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.

Researchers now know that MS starts way earlier than the clinical onset, creating the real possibility that MS could one day be controlled.

At ASHG in Boston, Eric Green received the society's Leadership Award and delivered an acceptance speech that moved the entire room.

Study findings suggest using the drug PF-06409577 to restore CDX2 in colon cancers could cut risk of recurrence and death by up to 50%.

BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS.

Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.

The peptide lab is designed to produce a range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates.

Researchers say findings help to bridge the structure of the genome to its function in managing how genes are turned on and off.

A new mechanism explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer.